ADC Therapeutics SA (ADCT)
SEC filings, financial facts, source resources, and Goglides workspace context for ADC Therapeutics SA.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
7Results6Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
ZETA: The growth headline is strong. The proof gate is quality, cash, and durability.
Zeta reported 50% Q1 revenue growth, raised 2026 guidance again, and launched Athena by Zeta. The proof gate is organic growth, super-scaled customers, adjusted EBITDA margin, and free cash flow.
OpenIONQ: Revenue is scaling, but the quantum proof gate is conversion plus losses.
Q1 2026 revenue beat, raised revenue guidance, and the first sixth-generation 256-qubit system sale. The proof gate is RPO conversion, organic revenue growth, and adjusted EBITDA loss discipline.
OpenGRAB: Grab is proving operating leverage, but lending and incentives are the watch items.
Grab reported Q1 2026 revenue growth, record adjusted EBITDA, and stronger on-demand GMV. The proof gate is adjusted EBITDA, adjusted free cash flow, loan quality, and incentive discipline.
OpenENPH: The solar downturn is real, but Enphase is testing a data-center power pivot.
Enphase reported Q1 2026 results and announced an IQ solid-state transformer program for AI data centers. The proof gate is revenue stabilization, battery shipments, non-GAAP gross margin, and IQ SST progress.
OpenDVLT Q1 2026 update: contract story is bigger, cash proof is still the test
A filing-led Datavault AI Q1 2026 earnings thesis focused on recognized revenue, tokenization contracts, cash conversion, losses, liquidity, and dilution risk.
OpenADC Therapeutics: the lymphoma readout trying to beat the royalty wall
ADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.
Open